The approval includes patients as young as three months old. 

This new measurement, researchers explained, can help clinicians target high-risk patients with more aggressive treatments. 

The study's authors examined data from more than 21,000 participants. 

The SGLT2 inhibitor was approved for this new indication based on results from the EMPEROR-Reduced trial.

Aortic stenosis is only seen in 1% of younger STEMI patients, but it becomes more and more common as patients get older. 

The procedure, like the hospital's first 99 TAVR cases, was a success. 

Moderate to severe aortic regurgitation was seen in 0.9% of patients after 30 days and 1.3% after one year.

The full Arctic Front line is now approved as a first-line treatment for heart rhythm issues. 

Working with 9/11 responders as retrospective subjects, researchers in mental health and computer science have shown AI language tools can help predict the course of PTSD.